Replimune Group, Inc. (REPL) — 10-K Filings
All 10-K filings from Replimune Group, Inc.. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
Replimune's Net Loss Widens to $240.5M Amid R&D Push
— May 22, 2025 Risk: high
Replimune Group, Inc. reported no revenue for the fiscal year ended March 31, 2025, consistent with its clinical-stage biotechnology status. The company posted -
Replimune Group, Inc. Files 2024 10-K
— May 16, 2024 Risk:
Replimune Group, Inc. (REPL) filed a Annual Report (10-K) with the SEC on May 16, 2024. Filed 10-K for the fiscal year ended March 31, 2024. Company is in the B
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX